^
Association details:
| Biomarker: | EGFR P772_H773insYNP + EGFR H773Y |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report
Published date:
07/23/2021
Excerpt:
...the patient accepted sintilimab plus pemetrexed every 3 weeks...the first case report of the clinical benefit of upfront immune checkpoint inhibitors (ICIs) plus chemotherapy for a brain metastatic NSCLC patient harboring EGFR exon 20 insertion mutation.
Secondary therapy:
carboplatin + pemetrexed
DOI:
10.1097/MD.0000000000026650
